title: Drug-eluting stents: the beginning of the end of restenosis?
abstract: In multiple clinical trials, patients who received drug-eluting stents instead of plain stents during percutaneous coronary interventions had rates of restenosis that were lower by roughly one half to three fourths, depending on how restenosis was defined and on the population studied. These stents will likely be used more and more as their indications evolve.
authors.affiliation: Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, OH 44195, USA.
authors.forename: Cameron
authors.initials: C
authors.lastname: Haery
authors.forename: Ravish
authors.initials: R
authors.lastname: Sachar
authors.forename: Stephen G
authors.initials: SG
authors.lastname: Ellis
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D023903:Coronary Restenosis / Q000517:prevention & control*; D004337:Drug Carriers; D016503:Drug Delivery Systems; D006801:Humans; D007962:Leukocytes / Q000187:drug effects; D032389:Myocytes, Smooth Muscle / Q000187:drug effects; D017239:Paclitaxel / Q000008:administration & dosage* / Q000494:pharmacology; D020123:Sirolimus / Q000008:administration & dosage* / Q000494:pharmacology; D015607:Stents
chemical_list: D004337:Drug Carriers; D017239:Paclitaxel; D020123:Sirolimus